Phase II, Multi-center, Open-Label, Single-Arm Study of Intratumoral Infusion of PRX321 in Subjects With Glioblastoma Multiforme at First Recurrence or Progression

Trial Profile

Phase II, Multi-center, Open-Label, Single-Arm Study of Intratumoral Infusion of PRX321 in Subjects With Glioblastoma Multiforme at First Recurrence or Progression

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 16 May 2013

At a glance

  • Drugs MDNA 55 (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Acronyms CLARITY-1
  • Most Recent Events

    • 17 May 2012 Status changed from not yet recruiting to withdrawn prior to recruitment.
    • 03 Dec 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top